Equities
  • Price (MXN)4,924.22
  • Today's Change0.00 / 0.00%
  • Shares traded210.00
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Nov 19 2024 11:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company is focused on improving the lives of people and animals around the world. It is engaged in the delivery of pharmaceuticals, healthcare products, and solutions. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

  • Revenue in USD (TTM)293.96bn
  • Net income in USD1.51bn
  • Incorporated2001
  • Employees42.00k
  • Location
    Cencora Inc1 West First AvenueCONSHOHOCKEN 19428United StatesUSA
  • Phone+1 (610) 727-7000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.cencora.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
COR:NYQ since
announced
Transaction
value
Retina Consultants PAAnnounced08 Nov 202408 Nov 2024Announced-0.57%--
Retina Midco IncAnnounced06 Nov 202406 Nov 2024Announced5.29%5.10bn
Data delayed at least 15 minutes, as of Nov 22 2024 14:57 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.